Lancet Oncol 2016 Aug
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Related Questions
New answer by Radiation Oncologist at Brigham and Women's Hospital (September 2, 2016)
RTOG 04-15 (N = 1092) – W Robert Lee et al.
Disease state: Low risk PC
Randomization: 73.8 Gy RT in 1.8 Gy fx’s versus 70 Gy RT in 2.5 Gy fx&rsqu...
New comment by Radiation Oncologist at Jacob E Locke MD PA ( January 30, 2022)
It is a standard perhaps but not the* standard as the trial paper concludes that "no significant overall survival difference was observed between the treatment arms."
Extrapo...
Do you prefer to treat patients with factors such as large prostate volume, significant comorbidities, anticoagulation use, history of TURP, or high A...
New answer by Radiation Oncologist at Fox Chase Cancer Center (May 15, 2021)
At Fox Chase, the overwhelming majority of our prostate patients who are treated with IMRT are treated with some form of hypofractionation (moderate hypofx or SbRT). Based on ...
The STAMPEDE trial recently published in Lancet used 55 Gy in 20 fractions but did not include dose constraints.
New comment by Radiation Oncologist at Lake Huron Medical Center ( February 25, 2021)
60 Gy in 20 fractions, as well.
Prospective single arm studies with short term follow-up were recently presented in abstract form (Kishan et al, IJROBP, Oct 2017; Mallick et al, IJRO...
New answer by Radiation Oncologist at The Oregon Clinic-Radiation Oncology West (October 23, 2020)
I agree 100% with Dr. @Amar U. Kishan. We shouldn't substitute an investigational option off-trial when we already have multiple effective, safe options. My hope is that SBRT ...